Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Colorado MEDtech, CMED -- Ignore unavailable to you. Want to Upgrade?

To: Andrew Q. Viet who wrote (166)	12/22/1998 6:51:00 AM
From: nanocap	Read Replies (1) \| Respond to of 288

Recent rise in stock price may have been too far too soon, but keep in mind the float is small (by Wall Street's standards), contract manufacturing business is very strong in many industries, CMED had record backlog at yearend, record first quarter, and new Y2K product/service (BioMed Y2K One) is doing well. Main risk at this point seems to be that they derive approximately 40% of revenue from two customers. But balance sheet is strong and an acquisition could alleviate the customer concentration concerns. If the company stays on track, the aforementioned attributes are the kind of fundamentals that will attract some attention on Wall Street. In the interest of full disclosure you should know that I write an investment newsletter and featured CMED in my November issue. Nonetheless, this company is doing a lot of things right and should continue to do well.